Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain LGND message board posts where the ticker symbol LGND has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest LGND SEC Filings

Filings Format Description Filing Date File/Film Number
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000886163-19-000201 Size: 6 KB
2019-11-13
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0000886163-19-000199 (34 Act)  Size: 8 MB
2019-11-08 001-33093
191204072
8-K  Documents   Interactive Data Current report, items 2.02 and 9.01
Acc-no: 0000886163-19-000191 (34 Act)  Size: 616 KB
2019-11-05 001-33093
191193271
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000886163-19-000188 Size: 6 KB
2019-10-16
8-K  Documents   Interactive Data Current report, items 5.02, 7.01, and 9.01
Acc-no: 0000886163-19-000186 (34 Act)  Size: 254 KB
2019-10-16 001-33093
191152013
3  Documents Initial statement of beneficial ownership of securities
Acc-no: 0000886163-19-000184 Size: 6 KB
2019-10-15
4/A  Documents [Amend] Statement of changes in beneficial ownership of securities
Acc-no: 0000886163-19-000177 Size: 6 KB
2019-09-24
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000886163-19-000175 Size: 6 KB
2019-09-23
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000886163-19-000174 Size: 6 KB
2019-09-23
8-K  Documents   Interactive Data Current report, item 8.01
Acc-no: 0000886163-19-000169 (34 Act)  Size: 183 KB
2019-09-12 001-33093
191089335
More LGND SEC Filings


Related news from
Fri, 06 Dec 2019
13:00:10 +0000
12 Biotech Stocks Primed For A Short Squeeze
Biotech investment is fraught with risk. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts. These binary events , however, provide an opportunity for making ...
Thu, 05 Dec 2019
16:31:04 +0000
Why Is Ligand (LGND) Up 5.3% Since Last Earnings Report?
Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mon, 02 Dec 2019
13:30:00 +0000
Ligand Enters into Worldwide OmniAb® Platform License Agreement with Sanofi
Ligand Pharmaceuticals Incorporated (LGND) announces it has entered into a worldwide OmniAb license agreement with Sanofi. Under the agreement, Sanofi will be able to use Ligand’s full OmniAb antibody discovery platform which includes OmniRat®, OmniFlic®, OmniMouse®, OmniChicken® and OmniClic™ in addition to Ligand’s patented antigen technology. OmniAb is licensed to over 40 corporate partners globally, and this deal with Sanofi adds to a growing portfolio of OmniAb discovery and clinical development programs with global fully-integrated pharmaceutical companies.
Tue, 19 Nov 2019
12:16:54 +0000
Edited Transcript of LGND earnings conference call or presentation 5-Nov-19 9:30pm GMT
Q3 2019 Ligand Pharmaceuticals Inc Earnings Call
Tue, 12 Nov 2019
13:30:00 +0000
Ligand Pharmaceuticals Ranked in Deloitte’s 2019 Technology Fast 500™
Ligand Pharmaceuticals Incorporated (LGND) today announced it ranked in Deloitte’s Technology Fast 500™, a listing of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies in North America now in its 25th year. “This is the third time Ligand has been included in the Technology Fast 500, and we are very pleased once again to be recognized by Deloitte for our rapid revenue growth,” said John Higgins, Chief Executive Officer of Ligand.
Fri, 08 Nov 2019
13:30:00 +0000
Ligand Presents Positive Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol
Presentation at the American Society of Nephrology Kidney Week 2019
Thu, 07 Nov 2019
13:30:00 +0000
Ligand to Participate in the Stephens 2019 Nashville Investment Conference
Ligand Pharmaceuticals Incorporated (LGND) announces that the company is scheduled to participate in the Stephens 2019 Nashville Investment Conference in Nashville, Tennessee. Matt Korenberg, CFO will attend for Ligand. Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines.
Wed, 06 Nov 2019
14:33:02 +0000
Ligand's (LGND) Q3 Earnings Miss Estimates, EPS View Down
Ligand (LGND) reports lower-than-expected third-quarter 2019 earnings. It also lowers outlook for 2019 earnings. However, revenues were better than expected.
Tue, 05 Nov 2019
21:02:00 +0000
Talem Therapeutics accesses the OmniAb® platform from Ligand Pharmaceuticals
VICTORIA , Nov. 5, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (IPATF), an industry leader in the discovery of novel, therapeutic antibodies, announces that Talem Therapeutics, a wholly-owned subsidiary, has entered into a worldwide OmniAb® platform license agreement with Ligand Pharmaceuticals (LGND). This license enables Talem to access Ligand's unique OmniAb platform for use with Talem's leading antibody discovery capabilities. Under the license, Talem has the right to develop and partner fully human antibodies in OmniRat®, OmniFlic®, OmniMouse®, OmniChicken®, and OmniClic™.
Tue, 05 Nov 2019
21:01:00 +0000
Ligand Reports Third Quarter 2019 Financial Results
Conference Call Begins at 4:30 p.m. Eastern Time Today
Tue, 29 Oct 2019
14:32:02 +0000
Analysts Estimate Ligand Pharmaceuticals (LGND) to Report a Decline in Earnings: What to Look Out for
Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fri, 25 Oct 2019
14:13:17 +0000
Is Ligand Pharmaceuticals Inc. (LGND) Going To Burn These Hedge Funds ?
Is Ligand Pharmaceuticals Inc. (NASDAQ:LGND) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably, but their consensus stock picks […]
Tue, 22 Oct 2019
20:01:00 +0000
Ligand to Report Third Quarter 2019 Results on November 5th
Ligand Pharmaceuticals Incorporated announced today plans to report third quarter 2019 financial results on November 5, 2019. Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the conference call.
Tue, 15 Oct 2019
13:00:00 +0000
Ligand Appoints Pharmaceutical Executive Sarah Boyce to its Board of Directors
Ligand Pharmaceuticals Incorporated (LGND) (“Ligand” or “the Company”) announces the appointment of Sarah Boyce to the Company's Board of Directors, effective today. Ms. Boyce currently serves as President and CEO of Avidity Biosciences, Inc., a privately held biotechnology company pioneering the use of antibody-oligonucleotide conjugates (AOC™) to treat rare muscle disorders and other serious diseases. Ms. Boyce's appointment increases the number of Ligand directors to nine.
Thu, 10 Oct 2019
14:08:49 +0000
Who Has Been Buying Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
Thu, 03 Oct 2019
12:00:00 +0000
ImmunoPrecise Strengthens Board of Directors with Antibody Business Leader, Brian Lundstrom
VICTORIA , Oct. 3, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF) a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, today announced the appointment of Brian Lundstrom to the company's Board of Directors. Trained in immunology and international business, Mr. Lundstrom has over 30 years' experience from mostly publicly traded companies with a focus on antibody therapeutics.
Mon, 23 Sep 2019
14:01:31 +0000
Sermonix Doses First Patient in Phase 2 Clinical Trial of Lasofoxifene for Targeted Precision Medicine Treatment of Women With ESR1 Mutations in Metastatic Breast Cancer
Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female-specific oncology products in the precision medicine metastatic breast cancer arena, today announced the enrollment and dosing of the first patient into a Phase 2 clinical trial of its lead investigational drug, lasofoxifene. The open-label, randomized, multi-center Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE, NCT03781063) study will assess the efficacy of oral lasofoxifene versus intramuscular fulvestrant for the treatment of postmenopausal women with locally advanced or metastatic estrogen receptor-positive (ER+)/HER2- breast cancer with an ESR1 mutation and progression-free survival as the primary endpoint.
Fri, 13 Sep 2019
12:42:12 +0000
Ligand (LGND) Surges: Stock Moves 6.3% Higher
Ligand (LGND) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Thu, 12 Sep 2019
10:41:00 +0000
Ligand Pharmaceuticals approves new $500 million stock buyback program
Ligand Pharmaceuticals Inc. disclosed Thursday that a new program to repurchase up to $500 million worth of stock over the next three years was approved by the company's board. Based on Wednesday's stock closing price of $91.80, the biopharmaceutical company could buy back up to 5.45 million shares, or 28.6% of the shares outstanding as of Aug. 7. The company said its previous $350 million stock repurchase program was terminated after it had bought back 2.97 million shares for about $350 million. Separately, Ligand disclosed that it had entered into a commercial platform license agreement with Hong Kong-based Kira Pharmaceuticals, which is focused on treatments for immunological diseases and cancer immunotherapy, in which Kira will be able to use OmniAb platform rodents and birds to discover fully human mono- and bispecific antibodies. Ligand will be eligible to receive milestone payments and tiered royalties for each product delivering an OmniAb antibody. The stock, which was still inactive in premarket trading, has slumped 32.4% year to date while the S&P 500 has gained 19.7%.
Thu, 29 Aug 2019
13:31:01 +0000
Why Is Ligand (LGND) Down 0.9% Since Last Earnings Report?
Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "It [ValueForum] has provided me with eye opening information on a wide scale. The collective wisdom of the membership is astounding and somewhat intimidating; but useful input is appreciated pretty universally." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2019, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards